These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
437 related items for PubMed ID: 20106343
1. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role. Liblau R. J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343 [Abstract] [Full Text] [Related]
4. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Proc Natl Acad Sci U S A; 2003 Nov 25; 100(24):14157-62. PubMed ID: 14614135 [Abstract] [Full Text] [Related]
7. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Teitelbaum D, Aharoni R, Klinger E, Kreitman R, Raymond E, Malley A, Shofti R, Sela M, Arnon R. Ann N Y Acad Sci; 2004 Dec 25; 1029():239-49. PubMed ID: 15681762 [Abstract] [Full Text] [Related]
8. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. Racke MK, Lovett-Racke AE. J Immunol; 2011 Feb 15; 186(4):1887-90. PubMed ID: 21289312 [Abstract] [Full Text] [Related]
13. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Aharoni R. Autoimmun Rev; 2013 Mar 15; 12(5):543-53. PubMed ID: 23051633 [Abstract] [Full Text] [Related]
14. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. Aharoni R, Eilam R, Stock A, Vainshtein A, Shezen E, Gal H, Friedman N, Arnon R. J Neuroimmunol; 2010 Aug 25; 225(1-2):100-11. PubMed ID: 20554028 [Abstract] [Full Text] [Related]